SFI
AQST icon

Susquehanna Fundamental Investments’s Aquestive Therapeutics AQST Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,644
Closed -$62K – 1692
2021
Q2 		$62K Buy
+15,644
New +$62.5K ﹤0.01% 1609

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna Fundamental Investments's AQST Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Aquestive Therapeutics (AQST) in Q3 2021, closing a stake of 15,644 shares — an estimated $62K sold.

Susquehanna Fundamental Investments first reported a position in AQST in Q2 2021 and held it in 1 quarter. The position peaked at $62K in Q2 2021. 46 funds tracked by Wall St. Rank hold AQST as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Aquestive Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 15,644 Aquestive Therapeutics shares in Q3 2021, an estimated $62K.
  • Susquehanna Fundamental Investments first reported a position in Aquestive Therapeutics in Q2 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Aquestive Therapeutics position peaked at $62K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.